Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-03-11
2008-03-11
Blanchard, David J. (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069600, C435S320100, C435S328000, C435S335000, C424S133100, C424S145100, C530S387300, C530S388230
Reexamination Certificate
active
07342110
ABSTRACT:
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
REFERENCES:
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5730982 (1998-03-01), Scheinberg
patent: 6417337 (2002-07-01), Anderson et al.
patent: 2002/0052479 (2002-05-01), Anderson et al.
patent: WO 94/10332 (1994-05-01), None
Gawinowicz et al. The Journal of immunology, 147(3):915-920, Aug. 1, 1991.
Roy et al., 1991, Anti-MY9-Blocked-Ricin: An Immunotoxin for Selective Targeting of Acute Myeloid Leukemia Cells,Blood77(11):2404-2412.
Sabbath et al., 1985, Heterogeneity of Clonogenic Cells in Acute Myeloblastic Leukemia,J. Clin. Invest.75:746-753.
LaRussa et al., 1992, Effects of Anti-CD33 Blocked Ricin Immunotoxin on the Capacity of CD34+Human Marrow Cells to Establish in vitro Hematopoiesis in Long-term Marrow Cultures,Exp. Hematol.20:442-448.
Griffin et al., 1984, A Monoclonal Antibody Reactive with Normal and Leukemic Human Myeloid Progenitor Cells,Leukemia Res.8:521-534.
Mason et al. eds., Leucocyte Typing VII White Cell Differentiation Antigens, pp. 777-778, Oxford University Press, 2002.
Anna M. Wu et al., “Arming antibodies: prospects and challenges for immunoconjugates”, Nature Biotechnology, vol. 23:9, Sep. 2005.
Zaho et al., “New Water Soluble CC-1065 Analog Prodrugs: Design, Synthesis and Evaluation”, American Chemical Society 224th National Meeting, Aug. 18-22, 2002.
Lutz et al., Proceedings of the American Association for Cancer Research Annual Meeting, vol. 43, p. 912, Mar. 2002.
Goldmacher et al., Proceedings of the American Association for Cancer Research Annual Meeting, vol. 43, p. 254, Mar. 2002.
R&D Focus Drug News, Nov. 12, 2001.
Paul, Fundamental Immunology, 3rd Ed., pp. 292-295, 1993.
Rudikoff et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity”, Proc. Natl. Sci. USA, Mar. 1982, vol. 79, pp. 1979-1983.
Coleman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions”, Research in Immunology, 1994, vol. 145, pp. 33-36.
Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution”, Science, Aug. 15, 1986, vol. 233, pp. 747-753.
Weitzhandler et al., “Analysis of Carbohydrates on IgG Preparations”, Journal of Pharmaceutical Sciences, Dec. 1994, vol. 83, No. 12, pp. 1670-1675.
CML NewyBytes, Oct. 24, 2001, www.cmlsupport.com/cmlnewsbytesarchives2.htm.
BioCentury Part II, vol. 9, No. 48, pp. B1-B22, Oct. 29, 2001.
Hoffee Mary G.
Lutz Robert J.
Tavares Daniel
Blanchard David J.
Immunogen Inc.
Sughrue & Mion, PLLC
LandOfFree
Anti-CD33 antibodies and method for treatment of acute... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD33 antibodies and method for treatment of acute..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD33 antibodies and method for treatment of acute... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2803836